Masitinib, an oral multi-targeted TK inhibitor primarily affecting KIT, as well as the receptors for fibroblast growth factor (FGF)3 and platelet-derived growth factor (PDGF), has been the subject of two clinical trials in MM (NCT01470131 and NCT00866138). Here, TKT is linked to Miyoshi myopathy.